<DOC>
	<DOCNO>NCT00755378</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , PK PD effect orally administer AZD8529 single ascending dos</brief_summary>
	<brief_title>AZD8529 Single Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject age 18 45 year ( inclusive ) Day 1 . Female subject must nonchild bear potential . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within 3 month first administration investigational prod Plasma donation within one month screen blood donation/blood loss &gt; 500mL 3 month prior screen Clinically relevant abnormality physical examination , vital sign , ECG , clinical chemistry , hematology urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Phase I</keyword>
</DOC>